Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.

Hepatology. 2002 Jan;35(1):182-9.

PMID:
11786975
3.

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S.

Clin Infect Dis. 2005 Feb 15;40(4):588-93. Epub 2005 Jan 21.

PMID:
15712082
4.

Hepatotoxicity in patients prescribed efavirenz or nevirapine.

Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzold D, Hartmann M.

Eur J Med Res. 2008 Jul 28;13(7):343-8.

PMID:
18700192
5.

NNRTI hepatotoxicity: efavirenz versus nevirapine.

Pulido F, Torralba M.

J HIV Ther. 2002 Nov;7 Suppl 2:S3-16. Review. English, Spanish. No abstract available.

PMID:
12735215
6.

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.

Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, Hung CC.

PLoS One. 2017 Feb 21;12(2):e0171596. doi: 10.1371/journal.pone.0171596. eCollection 2017.

7.

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.

Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA.

AIDS. 2003 Oct 17;17(15):2191-9.

PMID:
14523276
8.

Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.

Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group.

Drug Saf. 2007;30(12):1161-9.

PMID:
18035868
9.

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.

Kontorinis N, Dieterich DT.

Semin Liver Dis. 2003 May;23(2):173-82. Review.

PMID:
12800070
10.

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.

Palmon R, Koo BC, Shoultz DA, Dieterich DT.

J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):340-5.

PMID:
11917237
11.
13.

Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.

Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E.

BMC Public Health. 2010 Mar 1;10:105. doi: 10.1186/1471-2458-10-105.

14.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
15.

Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.

Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):426-31.

PMID:
11511818
16.

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

Rivero A, Mira JA, Pineda JA.

J Antimicrob Chemother. 2007 Mar;59(3):342-6. Epub 2007 Jan 25. Review.

PMID:
17255142
17.

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.

Manfredi R, Calza L, Chiodo F.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):492-502.

PMID:
15021314
18.

Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.

Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, Schlech WF, Katabira ET.

Afr Health Sci. 2011 Mar;11(1):16-23.

19.

Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.

Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA; COINS Study Team.

HIV Clin Trials. 2012 Mar-Apr;13(2):61-9. doi: 10.1310/hct1302-61.

PMID:
22510353
20.

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.

Martín-Carbonero L, Núñez M, González-Lahoz J, Soriano V.

HIV Clin Trials. 2003 Mar-Apr;4(2):115-20.

PMID:
12671779

Supplemental Content

Support Center